CJC-1295 + Ipamorelin Blend combines a growth hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue (GHS) for synergistic GH axis stimulation. CJC-1295 (without DAC) extends GHRH signaling while Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) without affecting cortisol or prolactin.
**Blend Composition:**
- CJC-1295 (No DAC): GHRH analog (Modified GRF 1-29)
- Ipamorelin: Selective GHS-R1a agonist pentapeptide
**Research Applications:**
- Synergistic GH pulse amplitude and frequency studies
- IGF-1 axis modulation without cortisol elevation
- Body composition and lean mass research
- Sleep architecture and GH secretion pattern analysis
- Age-related GH decline countermeasure studies
**Quality Standards:**
- Each component: ≥99% purity verified by HPLC
- Third-party tested with COA included
*FOR RESEARCH USE ONLY. Not for human consumption.*
Researchers should refer to peer-reviewed publications for primary sources on this compound. CJC-1295 + Ipamorelin is sold strictly for laboratory research use and is not intended for human or veterinary use.